XDx, Inc. has signed a collaborative pharmacogenomics agreement with Bristol-Myers Squibb focused on identifying biomarkers for Systemic Lupus Erythematosus (SLE) for clinical diagnostic purposes associated with the development of BMS’ rheumatoid arthritis drug Orencia. XDx will receive an upfront payment in addition to success-based milestone payments. XDx will receive commercial rights to certain diagnostic applications resulting from the collaboration. “This collaborative agreemen...